Tampere ImmunoExcellence (TIE) – Vaccines and Immunomodulation Platform
Vaccines are one of the great success stories of medicine. TAU has a unique position nationally in the vaccine and immunomodulation profiling area. This is based on research conducted in the early stages of the vaccine and immunomodulation development chain (such as target discovery, vaccine immunology, pharmacology and toxicology, preclinical studies with advanced disease models) combined with an outstanding nation-wide clinical vaccine trial network (Vaccine Research Center; 150 clinical vaccine trials). There are also has considerable expertise in infectious disease epidemiology for studying the impact (effectiveness and herd effect) of vaccinations at the population level, which links the impact of vaccines and vaccination programmes to national health and the economy. This tradition has created a nationally unique and internationally competitive vaccine cluster at TAU. The focus of the TIE Platform is to
1) connect the internationally recognised clinical vaccine studies with immunological basic research
2) identify targets suitable for immunomodulation
3) establish a strong vaccine development centre capable of translating innovations from the basic research to preclinical studies and clinical phases
4) support research career development and researcher mobility at TAU for the renewal of science
The program is funded by Academy of Finland under Profi4 program.